Bristol Myers Squibb has picked up a nod in the USA for its anemia med Reblozyl (luspatercept-aamt), a first-in-class therapy which promotes late-stage red bloo 30 August 2023
The European Commission (EC) has approved the extension of the Evrysdi (risdiplam) European Union (EU) marketing authorization to include infants with a clinica 29 August 2023
Although Latin America has a broad portfolio of innovative medicines to treat orphan diseases and cancer, only 13% of patients who would benefit from these ther 18 August 2023
French drugmaker Ipsen has won a landmark US approval of Sohonos (palovarotene) for an ultra-rare bone disease, having been rebuffed last month in its efforts t 17 August 2023
Privately-held drugmaker Chiesi has secured approval from the British medicines regulator for Elfabrio (pegunigalsidase alfa) in Fabry disease (FD). 16 August 2023
Swedish biopharma Calliditas Therapeutics continues to press for full approval of Nefecon/Tarpeyo (budesonide) delayed release capsules/Kinpeygo. 15 August 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.